Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cellegy, Biosyn deal

CLGY said it will acquire Biosyn for 2.5 million shares, valuing Biosyn at $10.6 million

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE